Breaking News

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ — Lynk Prescription drugs Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an impressive clinical phase organization, announced that it experienced dosed the to start with affected individual with LNK01001 in its Stage II clinical trial on topics with atopic dermatitis (Ad). LNK01001 is a selective JAK1 inhibitor for the procedure of autoimmune ailments. The clinical examine is built to appraise the protection and efficacy of LNK01001 capsules in adult patients with average to critical atopic dermatitis.

Atopic dermatitis is a continual, relapsing, inflammatory pores and skin condition that usually happens on the deal with, neck, elbow fossa and so forth. The people with reasonable to serious atopic dermatitis have repeated episodes of severe pruritus and long-term eczema-like pores and skin lesions as the major scientific manifestations, frequently merged with other atopic disorders this kind of as allergic rhinitis and bronchial asthma, which severely has an effect on the quality of lifestyle. LNK01001 is an progressive drug made by Lynk Prescribed drugs. It is applied for the procedure of autoimmune health conditions and is now in stage II experiments for rheumatoid arthritis and ankylosing spondylitis.

Professor Zhang Jianzhong, the principal investigator of this analyze, the 13th Director in the Dermatology Division of the Chinese Medical Association and Director of the Dermatology Department at Peking College People’s Clinic, mentioned, “Atopic dermatitis is a continual disease with a protracted study course of signs, which severely influences the patients’ top quality of existence and provides terrific stress and mental anxiety to their households and culture LNK01001 has demonstrated a great basic safety profile in healthy topics, and we be expecting that it will also have superb efficacy and security in individual trials.”

Dr. Sherry Weigand, the main healthcare officer of Lynk Pharmaceuticals, reported, “Atopic dermatitis has a profound unfavorable bodily, psychosocial and economic effect on affected clients and their people. It calls for a extended-term condition management. LNK01001 is an innovative prospect drug with wonderful prospective for the treatment method of autoimmune health conditions this kind of as atopic dermatitis. We will attempt to advance the clinical review of LNK01001 promptly for the early benefit of patients by working alongside one another with investigators with the objective of meeting the requirements of sufferers.”

About Lynk Pharmaceuticals:

Lynk Prescribed drugs, a scientific stage firm, was started in 2018 by senior drug R&D professionals and executives from Pfizer, Merck and Johnson & Johnson. Lynk Prescription drugs is devoted to the discovery and enhancement of innovative medicines for the treatment of most cancers, as properly as immune and inflammatory illnesses. Driven by a greater purpose, Lynk Prescribed drugs aims to be a current market chief to handle unmet health care requires by the progress of progressive therapies. To date, Lynk Prescribed drugs has independently created a range of Class I clinical progressive new medication, and independently as well as jointly with its US associate launched a quantity of clinical scientific studies globally. For more data about Lynk Pharmaceuticals, be sure to stop by: https://www.lynkpharma.com.

Resource Lynk Pharmaceuticals

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis